HomeCONGRESS

CONGRESS

View Category
Day 1

PARTNER to 5 years. TAVR is an effective alternative to surgery in high risk patients

This study included 699 patients with severe aortic stenosis and high surgical risk of whom 348 received...
solaci -
Learn More
Day 1

Improved survival after out-of-hospital cardiac arrest with the use of automated external defibrillators

This study included patients presenting out of hospital cardiac arrest between 2006 and 2012 in The Netherlands...
solaci -
Learn More
Day 1

Coronary flow reserve is associated to adverse events regardless angiographic severity.

This study included 329 consecutive patients derived to coronary angiography based on myocardial perfusion tests or PET...
solaci -
Learn More
Day 1

ITALIC PLUS: 6 months of double antiaggregation for no less than 24 months

Article This multicenter study included patients receiving the second generation stent XIENCE V (Abbott Vascular) randomized to 6...
solaci -
Learn More
Day 1

DAPT TRIAL: double antiaggregation remains controversial

Article This multicenter randomized control study with placebo was designed to determine the risks and benefits of double...
solaci -
Learn More
Day 1

ISAR-SAFE: 6 vs. 12 month clopidogrel administration after DES implantation

The aim of this randomized double blind control trial was to validate the safety and efficacy of...
solaci -
Learn More
Day 1

Reduction of ischemic events after 30 months of prasugrel following TAXUS stent implantation

Article The TAXUS Liberté Post Approval study included patients treated with TAXUS paclitaxel DES receiving prasugrel for 12...
solaci -
Learn More
Day 2

IMPROVE-IT Trial: Finally the association of ezetimibe and simvastatin reduces events vs. simvastatin monotherapy

This is a multicenter, randomized, double blind study designed to test the hypothesis that the combination of...
solaci -
Learn More